Abstract Details

Title Real-world experience with Ocrelizumab in Multiple Sclerosis patients: Two years follow up in Qatar

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 070

Objective This study evaluates the generalizability of data from Ocrelizumab phase 3 clinical trials and its effectiveness in a real-world setting of an Arab population within a rapidly developing country such as Qatar.

Background

Ocrelizumab was FDA approved in 2017 as the newest drug for the treatment of both relapsing-remitting (RRMS) and primary progressive multiple sclerosis (PPMS). OPERA I/II, the major clinical trials, for RRMS shows it is highly efficacious in controlling clinical and radiological activity with a good safety profile and generalizability.

Design/Methods

In this retrospective longitudinal cohort study patients were between 18-75 years old; had a confirmed MS; started Ocrelizumab after physician approval; received minimum 3 infusions and 24 months follow up.

Primary outcomes: Clinical relapses, baseline and monitoring imaging and adverse events.

Secondary outcomes: Demographics, disability outcomes and prior disease-modifying therapies.

Results

Of 83 patients, 65 met inclusion criteria. Mean age was 38.7, 58.5% were male, 31.7% were treatment-naive, 52 had RRMS, 5 had PPMS and 3 had SPMS.

Average duration of disease and number of infusions was 7.75 years and 3.2 respectively. Average number of gadolinium-enhancing lesions on baseline MRI was 1.27 and 0.07 after treatment. 11 patients had mild adverse events (infusion-related reactions), 13 had URTIs with 1 patient having COVID pneumonia, and 1 patient had UTI. Two patients developed cancer while on treatment.

Compared to OPERA I/II, patients in Qatar were older (mean age of 38.7 vs. 37.1 and 37.2), mostly male (58.5% vs. 65.9% and 65.0%), had similar mean EDSS score (2.57±2.67 vs 2.86±1.24 and 2.78±1.30) but longer duration of disease (7.75±6.72 vs. 6.7±6.4 and 6.7±6.1).

Conclusions Ocrelizumab is highly effective for the treatment of MS, especially in this Arab population with a long follow-up period. Compared to previous clinical trials, patients in Qatar had different demographic characteristics, with longer disease durations and fewer enhancing lesions at baseline.

Authors/Disclosures
Wajiha Yousuf, MD PRESENTER	Dr. Yousuf has nothing to disclose.
	No disclosure on file
	No disclosure on file
Tehniyat Baig, MD (NewYork Presbyterian / Weill Cornell Medical Center)	Ms. Baig has nothing to disclose.
Beatriz Garcia Canibano, MD (Hamad Medical Corporation)	Dr. Garcia Canibano has nothing to disclose.
Dirk T. Deleu, MD, PhD, FRCP, FAAN (Hamad Medical Corporation/Weill Cornell MC)	Dr. Deleu has nothing to disclose.

��ɫ��

��ɫ��